DexComvs.Eli Lilly
DXCM vs LLY · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
Eli Lilly is about 33× larger than DexCom by market cap; DexCom trades at the lower P/E (34.5 vs 43.2); year to date, DexCom leads (+37.2% vs +16.0%).
Side by side
| DXCM | LLY | |
|---|---|---|
| Market cap | $34.5B | $1.2T |
| Price | $89.16 | $1,233.66 |
| Today | −2.1% | −1.1% |
| Return YTD | +37.2% | +16.0% |
| Return 1Y | +10.7% | +75.2% |
| P/E | 34.5 | 43.2 |
| P/S | 6.9 | 14.5 |
| P/B | 13.2 | 34.0 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
DexComDXCM
Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.
Full DXCM profile →Eli LillyLLY
Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.
Full LLY profile →More DXCM & LLY comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.